Innovax-ILT

RSS

Avian infectious laryngotracheitis and Marek’s disease vaccine (live recombinant)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Innovax-ILT. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Innovax-ILT.

For practical information about using Innovax-ILT, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 25/07/2018

Authorisation details

Product details
Name
Innovax-ILT
Agency product number
EMEA/V/C/003869
Active substance
Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus
International non-proprietary name (INN) or common name
Avian infectious laryngotracheitis and Marek’s disease vaccine (live recombinant)
Species
Chicken
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI01AD03
Publication details
Marketing-authorisation holder
Intervet International B.V.
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
03/07/2015
Contact address
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

04/04/2018 Innovax-ILT - EMEA/V/C/003869 - IAIN/0002

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • IMMUNOLOGICALS FOR AVES
  • live viral vaccines for domestic fowls

Therapeutic indication

For active immunisation of one-day-old chicks to reduce mortality, clinical signs and lesions due to infection with avian infectious laryngotracheitis (ILT) virus and Marek’s disease (MD) virus.

Assessment history

How useful was this page?

Add your rating